3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
18
Prostatic Neoplasms
16
Colorectal Neoplasms
14
Neoplasms
12
Hematopoietic and Lymphatic System Neoplasm
11
Lung Neoplasms
8
Hematologic Neoplasms
8
Ovarian Neoplasms
5
Multiple Myeloma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Malignant Solid Neoplasm
4
Lymphoma
4
Urinary Bladder Neoplasms
3
Hematopoietic and Lymphoid System Neoplasm
3
Endometrial Neoplasms
3
Advanced Malignant Solid Neoplasm
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Cancer, Papillary
2
Pancreatic Neoplasms
2
Oropharyngeal Neoplasms
2
Obesity-Related Malignant Neoplasm
2
Mouth Neoplasms
2
Motor Activity
2
Melanoma
2
Malignant Female Reproductive System Neoplasm
2
Leukemia
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Head and Neck Neoplasms
2
Interventions
pembrolizumab
3
durvalumab
3
Paclitaxel
3
Doxorubicin
3
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Interviews as Topic
×
1 year
×
Clear all
No trials found.